[go: up one dir, main page]

WO1997031655A3 - Modified cytokines for therapeutic use - Google Patents

Modified cytokines for therapeutic use Download PDF

Info

Publication number
WO1997031655A3
WO1997031655A3 PCT/EP1997/000704 EP9700704W WO9731655A3 WO 1997031655 A3 WO1997031655 A3 WO 1997031655A3 EP 9700704 W EP9700704 W EP 9700704W WO 9731655 A3 WO9731655 A3 WO 9731655A3
Authority
WO
WIPO (PCT)
Prior art keywords
component
cytokines
therapeutic use
modified cytokines
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1997/000704
Other languages
French (fr)
Other versions
WO1997031655A2 (en
Inventor
Angelo Corti
Antonio Siccardi
Paolo Dellabona
Giulia Casorati
Micaela Pelagi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SAN RAFFAELE CENTRO FOND
Original Assignee
SAN RAFFAELE CENTRO FOND
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SAN RAFFAELE CENTRO FOND filed Critical SAN RAFFAELE CENTRO FOND
Priority to JP9530545A priority Critical patent/JP2000506835A/en
Priority to AU17694/97A priority patent/AU1769497A/en
Priority to EP97903285A priority patent/EP0885015A2/en
Publication of WO1997031655A2 publication Critical patent/WO1997031655A2/en
Publication of WO1997031655A3 publication Critical patent/WO1997031655A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The object of the present invention is a new method and new products for the therapeutic use of cytokines. The method is based on the sequential administration of a component A (e.g. a biotinylated antibody) able to deliver onto a particular pathologic target a second component B (e.g. avidin), followed by a component able to bind the component B (component C) (e.g. biotin), conjugated with the cytokines. The method permits to increase the local concentration of the modified cytokines (C-cytokines) through the interaction with the 'artificial' receptor B and to cause a local biologic response mediated by 'natural' receptors.
PCT/EP1997/000704 1996-02-27 1997-02-14 Modified cytokines for therapeutic use Ceased WO1997031655A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP9530545A JP2000506835A (en) 1996-02-27 1997-02-14 Modified cytokines for therapy
AU17694/97A AU1769497A (en) 1996-02-27 1997-02-14 Modified cytokines for therapeutic use
EP97903285A EP0885015A2 (en) 1996-02-27 1997-02-14 Modified cytokines for therapeutic use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI96A000358 1996-02-27
IT96MI000358A IT1282692B1 (en) 1996-02-27 1996-02-27 CYTOKINES MODIFIED FOR THERAPY USE

Publications (2)

Publication Number Publication Date
WO1997031655A2 WO1997031655A2 (en) 1997-09-04
WO1997031655A3 true WO1997031655A3 (en) 1997-11-13

Family

ID=11373397

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/000704 Ceased WO1997031655A2 (en) 1996-02-27 1997-02-14 Modified cytokines for therapeutic use

Country Status (6)

Country Link
EP (1) EP0885015A2 (en)
JP (1) JP2000506835A (en)
AU (1) AU1769497A (en)
CA (1) CA2247308A1 (en)
IT (1) IT1282692B1 (en)
WO (1) WO1997031655A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2783528A1 (en) * 1998-08-28 2000-03-24 Commissariat Energie Atomique Synthesis of labeled chemokine, useful for developing anti-inflammatory and antiviral agents uses conventional peptide synthesis with label attached to sidechain at predetermined position
WO2000012554A1 (en) * 1998-08-28 2000-03-09 Commissariat A L'energie Atomique Method for marked chemokine synthesis, marked chemokine and analysis kit
DE19845798A1 (en) * 1998-09-29 2000-04-13 Schering Ag Use of neoangiogenesis markers for diagnosis and therapy of tumors, agents containing them, and methods for their production
US9358307B2 (en) * 2008-01-25 2016-06-07 Gavish-Galilee Bio Applications Ltd. Targeting of innate immune response to tumor site
EA201892619A1 (en) * 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
UY36041A (en) 2014-03-21 2015-09-30 Abbvie Inc ANTI-EGFR ANTIBODY AND DRUG ANTIBODIES AND CONJUGATES
DK3458479T3 (en) 2016-06-08 2021-02-08 Abbvie Inc ANTI-B7-H3 ANTIBODIES AND ANTIBODY-MEDICINE CONJUGATES
US20200338209A1 (en) 2016-06-08 2020-10-29 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
EP3468993A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
WO2017214456A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
CN118562004A (en) 2016-12-16 2024-08-30 蓝鳍生物医药公司 Anti-CUB domain-containing protein 1 (CDCP 1) antibodies, antibody drug conjugates, and methods of use thereof
US11932694B2 (en) 2017-04-19 2024-03-19 Bluefin Biomedicine, Inc. Anti-VTCN1 antibodies and antibody drug conjugates
EP3638697A4 (en) 2017-06-12 2021-07-07 Bluefin Biomedicine, Inc. ANTI-IL1RAP ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
AR124681A1 (en) 2021-01-20 2023-04-26 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
WO2025126157A1 (en) 2023-12-15 2025-06-19 Advesya Anti-il-1rap binding domains and antibody-drug conjugates thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018325A1 (en) * 1993-02-03 1994-08-18 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
WO1995014493A1 (en) * 1993-11-23 1995-06-01 Neorx Corporation Three-step pretargeting methods and compounds
WO1995015979A1 (en) * 1993-12-07 1995-06-15 Neorx Corporation Pretargeting methods and compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018325A1 (en) * 1993-02-03 1994-08-18 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
WO1995014493A1 (en) * 1993-11-23 1995-06-01 Neorx Corporation Three-step pretargeting methods and compounds
WO1995015979A1 (en) * 1993-12-07 1995-06-15 Neorx Corporation Pretargeting methods and compounds

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
6TH INT. TUMOR NECROSIS FACTOR CONGRESS, 8 May 1996 (1996-05-08) - 12 May 1996 (1996-05-12), RHODES (GREECE) *
CHEMICAL ABSTRACTS, vol. 124, no. 11, 11 March 1996, Columbus, Ohio, US; abstract no. 142954, VODYANIK, M. A. ET AL: "Flow cytometric detection of two types of tumor necrosis factor alpha (TNF) receptors by biotinamidocaproyl-TNF in human tumor cells" XP002040778 *
CORTI A. ET AL.: "TUMOR CELL TARGETING WITH ANTIBODY-AVIDIN COMPLEXES AND BIOTINYLATED TNF.", EUROPEAN CYTOKINE NETWORK, vol. 7, no. 2, 1996, pages 289 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; XP002040779 *
EKSP. ONKOL. (1995), 17(1), 11-17 CODEN: EKSODD;ISSN: 0204-3564, 1995 *
STONE D. ET AL.: "Pretargeting as a delivery system for tumor-specific localization of TNF-alpha.", PROCEEDINGS OF THE AMERICAN ASSOC. FOR CANCER RES., vol. 37, March 1996 (1996-03-01), pages 484, XP002040787 *

Also Published As

Publication number Publication date
AU1769497A (en) 1997-09-16
ITMI960358A0 (en) 1996-02-27
ITMI960358A1 (en) 1997-08-27
EP0885015A2 (en) 1998-12-23
IT1282692B1 (en) 1998-03-31
WO1997031655A2 (en) 1997-09-04
JP2000506835A (en) 2000-06-06
CA2247308A1 (en) 1997-09-04

Similar Documents

Publication Publication Date Title
WO1997031655A3 (en) Modified cytokines for therapeutic use
EP1958965A3 (en) Agonist antibodies to a musk receptor, and their therapeutic uses
AU9648098A (en) Adenosine a3 receptor antagonists
EP1752465A3 (en) Linear VH-CH1-VH-CH1 heavy chain antibody fragment
PL327132A1 (en) Antagonists of the gonadotrophin liberating hormone
MX9707021A (en) Il-17 receptor.
WO1998028424A3 (en) Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
CA2114015A1 (en) Recombinant antibodies for human therapy
AU2329897A (en) Monoclonal antibodies specific for the platelet derived growth factor beta receptor and methods of use thereof
AU7692996A (en) Receptor antagonists
ZA964383B (en) Hepatocyte growth factor receptor antagonists and uses thereof.
AU3633997A (en) Chemokine receptor antagonists
AU2721797A (en) Artificial antibodies to corticosteroids prepared by molecular imprinting
AU3659897A (en) Chemokine receptor antagonists and methods of use therefor
AU5196996A (en) Adhesion receptor antagonists
EP1162264A3 (en) Chimeric hormone receptor
EA199900331A1 (en) PREPARATION FROM COATED PARTICLES
AU4552497A (en) Novel carboxylic acid derivatives, their preparation and use as mixed eta/etb receptor antagonists
WO1997010824A8 (en) Use of 5ht1b receptor antagonist for the treatment of vascular disease
AU1230795A (en) Adhesion receptor antagonists
AU5641798A (en) Artificial antibodies, method of producing the same and use thereof
AU3661895A (en) Adhesion receptor antagonists
AU7289196A (en) Combination of ltd, receptor antagonists with glucocorticosteroids
WO1997007209A3 (en) Receptor
AU2093297A (en) Use of 5-ht1a receptor antagonists for the treatment of urinary incontinence

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2247308

Country of ref document: CA

Ref country code: CA

Ref document number: 2247308

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997903285

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997903285

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1997903285

Country of ref document: EP